Sex: M
Vaccine: COVID19
Symptoms: Antibody test, Body temperature, COVID-19, Chest X-ray, Drug ineffective
Clinical narrative: Covid-19/Breakthrough Infection; Covid-19/Breakthrough Infection; This is a literature report.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for COVID-19 immunisation. Relevant medical history included: "Hematologic malignancies" (ongoing). The patient's concomitant medications were not reported. The following information was reported: drug ineffective (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Covid-19/Breakthrough Infection". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 antibody test: positive.  Follow-up (25Jan2022):This is a literature report. This is a follow-up report based on the receipt of the publication; the case has been updated to include additional information identified in the publication. Updated information: reporter and literature information were updated; medical history, lab data were updated; product indication and dosage was updated, outcome of the event was updated as recovered.  Patient is a 63-year-old male with a history of high-grade myelodysplastic syndrome, diagnosed 22Jul2019 and treated with nice cycles of a clinical trial with magrolimab in combination with azacytidine, completed 12Jun2020, followed by matched unrelated donor allogeneic stem cell transplantation on 21Jul2020. His transplant course was complicated by chronic GVHD requiring prednisone and ECP twice weekly (last session 29Jul2021) along with post-transplant cyclophosphamide, rapamycin, and mycophenolate mofetil. After his last session of photopheresis, the patient was hospitalized for a Cutibacterium acnes bacteremia, treated with a planned 14 days of ceftriaxone. But two days after this hospital discharge, the patient presented to the hospital with ongoing fevers of 103.1oF. His physical exam was noteworthy for tachycardia and mild hypoxia with an oxygen saturation of 94%. A comprehensive nasopharyngeal respiratory viral panel was obtained, which was positive for SARS-CoV-2 by PCR. Chest radiography showed a possible peribronchial wall thickening, and hazy basilar opacities suggestive of atelectasis. Based on the patient's clinical presentation, he was diagnosed with moderate COVID-19 infection and was deemed an appropriate candidate for casirivimab/imdevimab infusion. With a history of completing amRNAvaccine series less than 6months prior at an external site (with unclear specific dates of the vaccinations), COVID-19 IgG (spike), semi-quantitative antibodies were obtained, and returned as undetectable three days later. The patient has remained outpatient without subsequent complications secondary to his COVID-19 infection.; Sender's Comments: The efficacy of a drug varies from one patient to another and can be affected by different factors; however, a contributory role of BNT162B2 to the reported event drug ineffective cannot be ruled out based on the limited information provided.,Linked Report(s) : US-PFIZER_INC-202200063708 Same article/ drug/event and different patient.